? Tissue Microfabrication Core The elucidation of biophysical mechanisms that lead to metabolic aberrations in tumors and, in turn, impact cancer progression, requires specialized capabilities for the manipulation of cells, biological materials, and tissues and for the development of computational models to evaluate hypotheses and interpret experimental data. Additionally, the assessment of the clinical relevance of these mechanisms and their translation toward therapeutic applications requires coordinated access to patient-derived samples with thorough clinical and genetic profiling and data basing. The Tissue Microfabrication Core will provide project investigators a shared infrastructure that satisfies these requirements. The Core will organize these capabilities into three distinct, but integrated aims that couple strongly to the projects and to the Biophysics and Metabolic Imaging Core:
Aim 1 will manage the acquisition, clinical and genomic characterization, data banking, and distribution of patient- derived tissues; the coordination of tissue transfer between sites will be a central task of this aim.
Aim 2 will support the development and fabrication of advanced culture platforms and microfluidic devices for the characterization of cells and biomaterials; it will also interact closely with Aim 1 on the development of new approaches for the propagation of patient-derived cells in engineered microenvironments and the Biophysics and Metabolic Imaging Core on compatibility with diverse modes of characterization.
Aim 3 will support metabolic analysis and experimental design and interpretation with a hierarchy of computational models spanning from linear models of metabolic flux through nonlinear models that allow for the incorporation of signaling and gene regulation to multiscale models of cell growth and interaction in the tumor microenvironment. This Core will work closely with the Biophysics and Metabolic Imaging Core on the development of new capabilities and the assurance of quality control across all Projects. The core leverages and unites established strengths at the host institutions: (i) clinical cancer care and translational cancer research at Weill Cornell Medical College (WCMC) and, in particular, the Institute for Precision Medicine (IPM) run by WCMC and New York-Presbyterian Hospital; (ii) innovation in the application of micro- and nanofabrication to the life sciences at Cornell's Centers for Nanobiotechnology (NBTC) and Nanoscale Science and Engineering (CNF); and (iii) leadership in the development of multi-scale computational models that link intracellular, intercellular and tissue scale processes at Purdue University. Integration between these capabilities in this Core will allow the Center to build a new dimension ? biophysical characterization ? into the Precision Medicine approach to cancer care.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
1U54CA210184-01
Application #
9187699
Study Section
Special Emphasis Panel (ZCA1-TCRB-T (M1))
Project Start
Project End
Budget Start
2016-07-01
Budget End
2017-06-30
Support Year
1
Fiscal Year
2016
Total Cost
$292,667
Indirect Cost
$109,676
Name
Cornell University
Department
Type
DUNS #
872612445
City
Ithaca
State
NY
Country
United States
Zip Code
14850
Goncalves, Marcus D; Hwang, Seo-Kyoung; Pauli, Chantal et al. (2018) Fenofibrate prevents skeletal muscle loss in mice with lung cancer. Proc Natl Acad Sci U S A 115:E743-E752
Iyengar, Neil M; Chen, I-Chun; Zhou, Xi K et al. (2018) Adiposity, Inflammation, and Breast Cancer Pathogenesis in Asian Women. Cancer Prev Res (Phila) 11:227-236
Zahid, H; Subbaramaiah, K; Iyengar, N M et al. (2018) Leptin regulation of the p53-HIF1?/PKM2-aromatase axis in breast adipose stromal cells: a novel mechanism for the obesity-breast cancer link. Int J Obes (Lond) 42:711-720
Hopkins, Benjamin D; Pauli, Chantal; Du, Xing et al. (2018) Suppression of insulin feedback enhances the efficacy of PI3K inhibitors. Nature 560:499-503
Croessmann, Sarah; Sheehan, Jonathan H; Lee, Kyung-Min et al. (2018) PIK3CA C2 Domain Deletions Hyperactivate Phosphoinositide 3-kinase (PI3K), Generate Oncogene Dependence, and Are Exquisitely Sensitive to PI3K? Inhibitors. Clin Cancer Res 24:1426-1435
Puca, Loredana; Bareja, Rohan; Prandi, Davide et al. (2018) Patient derived organoids to model rare prostate cancer phenotypes. Nat Commun 9:2404
van Helvert, Sjoerd; Storm, Cornelis; Friedl, Peter (2018) Mechanoreciprocity in cell migration. Nat Cell Biol 20:8-20
Beunk, Lianne; Brown, Kari; Nagtegaal, Iris et al. (2018) Cancer invasion into musculature: Mechanics, molecules and implications. Semin Cell Dev Biol :
Lourenço, Bianca N; Springer, Nora L; Ferreira, Daniel et al. (2018) CD44v6 increases gastric cancer malignant phenotype by modulating adipose stromal cell-mediated ECM remodeling. Integr Biol (Camb) 10:145-158
Elacqua, Joshua J; McGregor, Alexandra L; Lammerding, Jan (2018) Automated analysis of cell migration and nuclear envelope rupture in confined environments. PLoS One 13:e0195664

Showing the most recent 10 out of 46 publications